Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.65 - $3.94 $296,245 - $707,399
179,543 Added 515.9%
214,345 $801,000
Q3 2023

Nov 14, 2023

SELL
$2.02 - $5.04 $848,672 - $2.12 Million
-420,135 Reduced 92.35%
34,802 $73,000
Q2 2023

Aug 14, 2023

SELL
$4.76 - $6.59 $895,746 - $1.24 Million
-188,182 Reduced 29.26%
454,937 $2.17 Million
Q1 2023

May 15, 2023

BUY
$4.24 - $11.12 $299,216 - $784,738
70,570 Added 12.33%
643,119 $3.67 Million
Q4 2022

Feb 14, 2023

BUY
$9.86 - $23.83 $3.1 Million - $7.48 Million
313,923 Added 121.38%
572,549 $5.78 Million
Q3 2022

Nov 14, 2022

SELL
$21.04 - $36.06 $2.28 Million - $3.91 Million
-108,436 Reduced 29.54%
258,626 $5.8 Million
Q2 2022

Aug 15, 2022

BUY
$17.78 - $42.39 $6.22 Million - $14.8 Million
350,056 Added 2058.43%
367,062 $9.1 Million
Q1 2022

May 16, 2022

BUY
$29.67 - $60.28 $190,184 - $386,394
6,410 Added 60.49%
17,006 $659,000
Q4 2021

Feb 14, 2022

SELL
$47.84 - $64.34 $3.37 Million - $4.53 Million
-70,438 Reduced 86.92%
10,596 $620,000
Q3 2021

Nov 15, 2021

BUY
$59.27 - $95.73 $3.69 Million - $5.96 Million
62,238 Added 331.12%
81,034 $4.8 Million
Q2 2021

Aug 16, 2021

SELL
$67.25 - $92.52 $1.63 Million - $2.25 Million
-24,283 Reduced 56.37%
18,796 $1.63 Million
Q1 2021

May 17, 2021

SELL
$72.16 - $117.4 $2.04 Million - $3.32 Million
-28,281 Reduced 39.63%
43,079 $3.55 Million
Q4 2020

Feb 16, 2021

SELL
$38.09 - $100.95 $575,616 - $1.53 Million
-15,112 Reduced 17.48%
71,360 $6.49 Million
Q3 2020

Nov 16, 2020

BUY
$30.41 - $40.5 $2.63 Million - $3.5 Million
86,372 Added 86372.0%
86,472 $3.46 Million
Q2 2020

Aug 14, 2020

BUY
$20.21 - $35.23 $2,021 - $3,522
100 New
100 $3,000
Q1 2020

May 15, 2020

SELL
$17.28 - $31.88 $764,069 - $1.41 Million
-44,217 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$13.39 - $20.73 $591,998 - $916,514
44,212 Added 884240.0%
44,217 $865,000
Q3 2019

Nov 14, 2019

SELL
$15.47 - $22.5 $76,468 - $111,217
-4,943 Reduced 99.9%
5 $0
Q2 2019

Aug 14, 2019

BUY
$15.61 - $20.44 $32,562 - $42,637
2,086 Added 72.89%
4,948 $100,000
Q1 2019

May 15, 2019

SELL
$13.15 - $18.71 $241,999 - $344,320
-18,403 Reduced 86.54%
2,862 $50,000
Q4 2018

Feb 14, 2019

BUY
$11.48 - $16.98 $244,122 - $361,079
21,265 New
21,265 $273,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $127M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.